{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:26:11Z","timestamp":1768080371685,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","annalsofvascularsurgery.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.avsg.2023.12.092","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T17:28:10Z","timestamp":1710523690000},"page":"185-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comparative Outcomes of Peripheral Vascular Interventions in Patients on Chronic Anticoagulation with Factor Xa Inhibitors and Vitamin K Antagonists"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-2140","authenticated-orcid":false,"given":"Joshua J.","family":"Huttler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Alameddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fachreza Aryo","family":"Damara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Pinto-","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Slade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassius Iyad","family":"Ochoa Chaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2023.12.092_bib1","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2023.12.092_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Anand","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2023.12.092_bib3","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2023.12.092_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jvs.2016.12.141","article-title":"Comparative effectiveness of anticoagulation on midterm infrainguinal bypass graft patency","volume":"66","author":"Liang","year":"2017","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.092_bib5","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jvs.2022.12.012","article-title":"Use of direct-acting oral anticoagulants associated with improved survival and bypass graft patency compared with warfarin after infrageniculate bypass","volume":"77","author":"Ebertz","year":"2023","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.092_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.avsg.2020.02.035","article-title":"Atrial fibrillation and surgical patients with peripheral arterial disease","volume":"67","author":"Gonz\u00e1lez-Fajardo","year":"2020","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.092_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.amjmed.2021.10.021","article-title":"The impact of atrial fibrillation on outcomes of peripheral arterial disease: analysis of routinely collected primary care data","volume":"135","author":"Vitalis","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.avsg.2023.12.092_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15580","article-title":"Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization","volume":"5","author":"Hess","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.avsg.2023.12.092_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1024\/0301-1526\/a001029","article-title":"Peripheral artery disease and the risk of venous thromboembolism","volume":"51","author":"Sykora","year":"2022","journal-title":"Vasa"},{"key":"10.1016\/j.avsg.2023.12.092_bib10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.amjmed.2020.08.026","article-title":"Peripheral arterial disease in patients with atrial fibrillation: the AFFIRM study","volume":"134","author":"Vitalis","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.avsg.2023.12.092_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.avsg.2023.12.092_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2023.12.092_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004699","article-title":"Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation and peripheral artery disease: insights from the ARISTOTLE trial","volume":"6","author":"Hu","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.avsg.2023.12.092_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/eurheartj\/eht492","article-title":"Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF","volume":"35","author":"Jones","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.avsg.2023.12.092_bib15","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/S0735-1097(16)32263-X","article-title":"Edoxaban versus warfarin in 841 patients with atrial fibrillation and peripheral arterial disease: insights from the Engage AF-TIMI 48 trial","volume":"67","author":"Cunningham","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2023.12.092_bib16","article-title":"Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study","volume":"359","author":"Jun","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.avsg.2023.12.092_bib17","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jvs.2012.03.016","article-title":"The society for vascular surgery vascular quality initiative","volume":"55","author":"Cronenwett","year":"2012","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.092_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for US medicare beneficiaries","volume":"4","author":"Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.avsg.2023.12.092_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.28033","article-title":"Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism","volume":"6","author":"Fang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.avsg.2023.12.092_bib20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2023.12.092_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2023.12.092_bib22","article-title":"Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation","volume":"3","author":"Bruins Slot","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.avsg.2023.12.092_bib23","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.avsg.2023.12.092_bib24","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jama.2014.1403","article-title":"Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation","volume":"311","author":"Bruins Slot","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2023.12.092_bib25","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/STROKEAHA.116.016275","article-title":"Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis","volume":"48","author":"Bai","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.avsg.2023.12.092_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274969","article-title":"Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding","volume":"17","author":"Cohen","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.avsg.2023.12.092_bib27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2023.12.092_bib28","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jvs.2017.02.052","article-title":"Safety and efficacy of rivaroxaban compared with warfarin in patients undergoing peripheral arterial procedures","volume":"66","author":"Talukdar","year":"2017","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.092_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005456","article-title":"Peripheral artery disease and transcatheter aortic valve replacement outcomes: a report from the society of thoracic surgeons\/American college of cardiology transcatheter therapy registry","volume":"10","author":"Fanaroff","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2023.12.092_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/circ.146.suppl_1.12311","article-title":"Abstract 12311: the impact of ejection fraction on major adverse limb events after lower extremity revascularization","volume":"146","author":"Jamil","year":"2022","journal-title":"Circulation"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509624000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509624000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T23:47:58Z","timestamp":1719877678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509624000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":30,"alternative-id":["S0890509624000992"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2023.12.092","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Outcomes of Peripheral Vascular Interventions in Patients on Chronic Anticoagulation with Factor Xa Inhibitors and Vitamin K Antagonists","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2023.12.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}